PeptideStack
5.2kquestions
20kanswers
220users

semaglutide

Page 19 of 20 · 470 questions tagged semaglutide.

470 questions · sorted by votes · page 19 of 20

4 votes4 answers6.1k views
Is STEP 8 a fair comparison of semaglutide against its comparator arm?

Concretely: STEP 8 · semaglutide. The claim is plausible, which is exactly why I want to check it. I am able to read a paper if someone points me at one. Has anyone…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
tirzepatide
tirzepatide

A dual GIP and GLP-1 receptor agonist. Questions here cover the SURPASS and SURMOUNT programmes, the practical differences from a pure GLP-1…

370 questions
asked by lucia_marchetti 19k · 14 months ago
4 votes 5 answers5.8k views
Is 30 °C an acceptable storage condition for lyophilised semaglutide?

For reference: 30 °C · semaglutide. Somebody stated this to me confidently and I would like to check it before repeating it. I would accept a well-reasoned negative…

storage
storage

Storage conditions and their evidence base: minus twenty degrees for powder, refrigerated for solution, protection from light, and what the…

701 questions
peptide-stability
peptide-stability

The chemistry of peptide degradation: deamidation, oxidation, hydrolysis, aggregation and fibrillation, and how temperature, pH, ionic strength,…

908 questions
shelf-life
shelf-life

How long a preparation remains within specification: labelled expiry for a sealed lyophilised vial, beyond-use dating after reconstitution, and…

327 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
asked by swab_and_wait 13k · 2 months ago
4 votes 5 answers5k views
What does SURMOUNT-2 actually establish about tirzepatide?

The particulars: SURMOUNT-2 · tirzepatide. I have the document in front of me and I can read the numbers. What I cannot do is interpret them. I am reasonably…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
cardiovascular
cardiovascular

Cardiovascular outcomes: the SELECT major-adverse-event result, SOUL, SUSTAIN 6 and REWIND, how to convert a hazard ratio into an absolute risk…

68 questions
tirzepatide
tirzepatide

A dual GIP and GLP-1 receptor agonist. Questions here cover the SURPASS and SURMOUNT programmes, the practical differences from a pure GLP-1…

370 questions
asked by kelvin_lam 7.6k · 5 months ago
4 votes5 answers4.7k views
Would you re-test semaglutide after four weeks at 25 °C, or accept the original certificate?

The case in front of me: semaglutide · four weeks · 25 °C. The failure mode I am trying to avoid is making this decision emotionally. I have twelve months in view and…

batch-testing
batch-testing

Testing at the batch or lot level: sampling plans, how many vials from a lot need testing to say anything about the lot, and the difference…

910 questions
peptide-stability
peptide-stability

The chemistry of peptide degradation: deamidation, oxidation, hydrolysis, aggregation and fibrillation, and how temperature, pH, ionic strength,…

908 questions
coa
coa

Certificates of analysis: what fields a useful one carries, how to tell a real analytical report from a marketing document, batch and lot…

771 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
asked by rania_haddad 13k · 20 days ago
4 votes3 answers4.6k views
Is SUSTAIN-6 a fair comparison of semaglutide against its comparator arm?

Numbers first: SUSTAIN-6 · semaglutide. I am asking for verification rather than opinion, ideally with something I can read myself. It is possible the evidence exists…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
tirzepatide
tirzepatide

A dual GIP and GLP-1 receptor agonist. Questions here cover the SURPASS and SURMOUNT programmes, the practical differences from a pure GLP-1…

370 questions
asked by Dr_Ravi_Selvarajah 35k · 6 months ago
4 votes0 answers4.2k views
Does fibrillation of semaglutide at 25 °C show up as a loss of content or of purity?

The specifics, since they change the answer: fibrillation · semaglutide · 25 °C. I would like the mechanism, because I want to be able to reason about the cases…

peptide-stability
peptide-stability

The chemistry of peptide degradation: deamidation, oxidation, hydrolysis, aggregation and fibrillation, and how temperature, pH, ionic strength,…

908 questions
content-assay
content-assay

Quantified content: how many milligrams of peptide are actually in the vial, measured against a calibrated reference standard. A separate test…

476 questions
purity
purity

Purity as chromatographic area per cent - the fraction of detected material that is your target peak. It says nothing about how much material is…

833 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
asked by fibre_or_fragment 13k · 2.1 years ago
4 votes5 answers3.2k views
What is the reported incidence of dizziness on semaglutide in STEP 8?

Numbers first: dizziness · semaglutide · STEP 8. I can parse the result. I am less sure what it licenses me to conclude. I have deliberately not looked at anyone…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
harm-reduction
harm-reduction

Reducing avoidable risk where a decision has already been made: independent verification before use, sterility practice, dose arithmetic checked…

472 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
asked by sasha_ferreira 9.4k · 4 months ago
4 votes0 answers2.5k views
How comparable are orforglipron and semaglutide on the evidence available?

For reference: orforglipron · semaglutide. Both of these get recommended confidently by different people, which suggests neither is obviously right. My constraints…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
tirzepatide
tirzepatide

A dual GIP and GLP-1 receptor agonist. Questions here cover the SURPASS and SURMOUNT programmes, the practical differences from a pure GLP-1…

370 questions
orforglipron
orforglipron

A non-peptide, orally bioavailable small-molecule GLP-1 receptor agonist studied in the ATTAIN programme. It is not a peptide, which changes…

219 questions
asked by leah_ferrers 12k · 9 months ago
4 votes5 answers2.5k views
Is injection-site erythema on semaglutide dose-dependent or dose-rate dependent?

What I am working with: injection-site erythema · semaglutide. I understand the observation; what I do not understand is the mechanism behind it. I have read the two…

injection-site-reaction
injection-site-reaction

Local reactions: erythema, induration, pruritus and nodules. Their relationship to injection depth, diluent composition, benzyl alcohol…

49 questions
titration
titration

Stepwise dose increases over weeks, why the label schedules exist at all, and what tolerability-driven deviation from a schedule looks like in…

456 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
asked by charge_state_3 16k · 3 months ago
4 votes5 answers2.2k views
What is the reported incidence of dizziness on semaglutide in STEP 5?

For reference: dizziness · semaglutide · STEP 5. I want to understand what this actually establishes, as opposed to what it is being used to imply. My concern is that…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
harm-reduction
harm-reduction

Reducing avoidable risk where a decision has already been made: independent verification before use, sterility practice, dose arithmetic checked…

472 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
asked by n_takahashi 29k · 3 months ago
4 votes0 answers1.3k views
What is the reported incidence of injection-site erythema on semaglutide in SELECT?

What I have: injection-site erythema · semaglutide · SELECT. I want to understand what this actually establishes, as opposed to what it is being used to imply. My…

injection-site-reaction
injection-site-reaction

Local reactions: erythema, induration, pruritus and nodules. Their relationship to injection depth, diluent composition, benzyl alcohol…

49 questions
clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
asked by a_lindgren 58k · 2 months ago
4 votes0 answers504 views
Can I reconstitute semaglutide at 3.33 mg/mL and still measure a small dose accurately?

Conditions: semaglutide · 3.33 mg/mL. I want to decide this in advance so that I am not deciding it under pressure later. Assume I will follow the plan I write down,…

diluent-volume
diluent-volume

Choosing how much diluent to add, which is really a question about what you want your measurement resolution to be. Larger volumes buy you…

295 questions
insulin-syringe
insulin-syringe

U-100 and U-40 insulin syringes as measuring instruments. A U-100 syringe is graduated in insulin units where 100 units equals 1 mL, so one unit…

244 questions
dosing-math
dosing-math

The arithmetic itself: milligrams to millilitres to insulin units, concentration after reconstitution, dose per draw, and vial-days per vial. Show…

764 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
asked by retest_please 9.7k · 16 days ago
3 votes 5 answers7.2k views
What does 96.8% purity on a C18 column actually tell me about a semaglutide vial?

Setup, so nobody has to ask: 96.8% · a C18 column · semaglutide. I would like help reading this properly rather than being told what conclusion to reach. I have the…

hplc
hplc

Reverse-phase high-performance liquid chromatography, the workhorse purity method. Column chemistry, mobile-phase choice, gradient slope,…

503 questions
purity
purity

Purity as chromatographic area per cent - the fraction of detected material that is your target peak. It says nothing about how much material is…

833 questions
coa
coa

Certificates of analysis: what fields a useful one carries, how to tell a real analytical report from a marketing document, batch and lot…

771 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
asked by nominal_ten 12k · 5 months ago
3 votes0 answers4.4k views
Is a 29G needle the right choice for drawing semaglutide at 20 mg/mL?

For reference: a 29G needle · semaglutide · 20 mg/mL. The comparison I want does not seem to exist anywhere in a form I can evaluate. I have read the arguments for…

needle-gauge
needle-gauge

Gauge and length selection, the trade-off between draw time and tissue trauma, coring risk with larger-bore needles, and why a fixed-needle…

91 questions
injection-technique
injection-technique

Technique questions: angle, pinch versus flat, aspiration, injection speed, air bubbles, and the handling steps that determine whether you deliver…

96 questions
dead-space
dead-space

The volume trapped in the syringe hub and needle after the plunger bottoms out. It is small in absolute terms and large as a fraction of a small…

117 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
asked by jo_vandeberg 23k · 17 months ago
3 votes 5 answers4.3k views
Does nausea at week four of semaglutide usually resolve without a dose change?

The case in front of me: nausea · four · semaglutide. This is a procedural question rather than a theoretical one, and I would like the procedure rather than the…

nausea
nausea

The dominant tolerability signal in every trial of the class: incidence, timing relative to a dose step, duration, and the distinction between…

55 questions
titration
titration

Stepwise dose increases over weeks, why the label schedules exist at all, and what tolerability-driven deviation from a schedule looks like in…

456 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
asked by fib4_reader 24k · 3 months ago
3 votes 3 answers2.3k views
Is there any published stability data for semaglutide at 37 °C?

Concretely: semaglutide · 37 °C. The claim is plausible, which is exactly why I want to check it. I am able to read a paper if someone points me at one. Is there data…

peptide-stability
peptide-stability

The chemistry of peptide degradation: deamidation, oxidation, hydrolysis, aggregation and fibrillation, and how temperature, pH, ionic strength,…

908 questions
storage
storage

Storage conditions and their evidence base: minus twenty degrees for powder, refrigerated for solution, protection from light, and what the…

701 questions
clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
asked by swab_and_wait 13k · 44 days ago
3 votes0 answers2.3k views
What does STEP 3 actually establish about semaglutide?

What I have: STEP 3 · semaglutide. This is presented as though it settles something, and I am not convinced it does. I have two documents that appear to disagree,…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
cardiovascular
cardiovascular

Cardiovascular outcomes: the SELECT major-adverse-event result, SOUL, SUSTAIN 6 and REWIND, how to convert a hazard ratio into an absolute risk…

68 questions
asked by m_haraldsen 21k · 8 months ago
3 votes5 answers2k views
Does the PIONEER-4 population resemble anyone asking about oral semaglutide here?

Conditions: PIONEER-4 · oral semaglutide. The figures are clear enough; the question is what they mean and what they do not. I can supply the numbers if the specifics…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
harm-reduction
harm-reduction

Reducing avoidable risk where a decision has already been made: independent verification before use, sterility practice, dose arithmetic checked…

472 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
oral-glp1
oral-glp1

Oral routes for GLP-1 receptor agonism: peptide formulations rescued by absorption enhancers such as SNAC, and true small molecules that need no…

219 questions
asked by threadlock7 19k · 8 days ago
2 votes5 answers24k views
What is the reported incidence of headache on semaglutide in STEP 5?

Stated plainly: headache · semaglutide · STEP 5. I would like help reading this properly rather than being told what conclusion to reach. I have the full report…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
harm-reduction
harm-reduction

Reducing avoidable risk where a decision has already been made: independent verification before use, sterility practice, dose arithmetic checked…

472 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
asked by two_two_micron 9.3k · 2.3 years ago
2 votes 5 answers23k views
What does SURMOUNT-3 actually establish about a GLP-1 receptor agonist?

What I am working with: SURMOUNT-3 · a GLP-1 receptor agonist. I would like help reading this properly rather than being told what conclusion to reach. I have the…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
cardiovascular
cardiovascular

Cardiovascular outcomes: the SELECT major-adverse-event result, SOUL, SUSTAIN 6 and REWIND, how to convert a hazard ratio into an absolute risk…

68 questions
asked by anouk_desmet 16k · 2.2 years ago
2 votes5 answers19k views
Does the STEP 1 population resemble anyone asking about semaglutide here?

The case in front of me: STEP 1 · semaglutide. The figures are clear enough; the question is what they mean and what they do not. I can supply the numbers if the…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
harm-reduction
harm-reduction

Reducing avoidable risk where a decision has already been made: independent verification before use, sterility practice, dose arithmetic checked…

472 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
asked by area_percent 9.9k · 21 months ago
2 votes 5 answers9.6k views
Why do two papers on SURMOUNT-1 report different headline figures?

This is a question about interpretation, not about whether to act — I will take action questions elsewhere. This is one of those things that everyone repeats and…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
dosing-math
dosing-math

The arithmetic itself: milligrams to millilitres to insulin units, concentration after reconstitution, dose per draw, and vial-days per vial. Show…

764 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
asked by assay_blank 45k · 2.3 years ago
2 votes 5 answers7.9k views
What should I make of a semaglutide documentation package that has no date of analysis?

The particulars: semaglutide · date of analysis. The figures are clear enough; the question is what they mean and what they do not. I can supply the numbers if the…

coa
coa

Certificates of analysis: what fields a useful one carries, how to tell a real analytical report from a marketing document, batch and lot…

771 questions
vendor-vetting
vendor-vetting

Evaluating a supplier on evidence rather than reputation: testing history across batches, whether certificates are batch-specific, how failures…

454 questions
batch-testing
batch-testing

Testing at the batch or lot level: sampling plans, how many vials from a lot need testing to say anything about the lot, and the difference…

910 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
asked by seven_day_half 31k · 17 months ago
2 votes4 answers4.8k views
Why does STEP 1 report two different weight-loss figures?

I have three data points across nine months, which I hope is enough to see a trend. This is presented as though it settles something, and I am not convinced it does.…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
dosing-math
dosing-math

The arithmetic itself: milligrams to millilitres to insulin units, concentration after reconstitution, dose per draw, and vial-days per vial. Show…

764 questions
asked by priya_menon 13k · 3 months ago